• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medecine et maladies infectieuses >Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)
【24h】

Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)

机译：在阿比让（象牙海岸）的HIV-1初治患者中依非韦伦和茚地那韦

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: The authors had for aim to compare the therapeutic efficiency and tolerance of 2 NRTI+efavirenz (EFV) versus 2 NRTI+indinavir (IDV) in HIV infected adults in Abidjan. METHODS: A retrospective and multicentric study was made on 327 HIV-1 naive patients, 142 in the EFV group and 185 in the IDV group followed in Abidjan from November 1998 to December 2003. The analysis concerned clinical advents (opportunistic infections) and immunovirological parameters (CD4, viral load). Patients received 2 NRTI such as AZT+3TC or D4T+3TC combined either with EFV or IDV. The principal judgement criterion was therapeutic failure. We assessed the percentage of patients with undetectable viral load and the frequency of grade 3-4 adverse effects after 24 months of follow-up. RESULTS: Clinical improvement of patients' state and regression of opportunistic infections were identical in the two groups. The average gain of CD4 was superior to 177 in EFV versus +219 in IDV (p=0.004). The percentage of patients with undetectable viral load was 66% for EFV versus 59% for IDV (p=0.04). The frequency of adverse effects was more elevated with EFV than IDV, 39% versus 23% (p=0.002) initially, but seemed to decrease later. CONCLUSION: HAART with EFV is at least as efficient as with IDV in terms of reduction of viral load and increased CD4 count and is an excellent low-cost first line treatment.
机译：目的：作者旨在比较2 NRTI +依法韦仑（EFV）与2 NRTI +茚地那韦（IDV）在阿比让的HIV感染成年人中的治疗效率和耐受性。方法：对1998年11月至2003年12月在阿比让进行的327例HIV-1初治患者，142例EFV组和185例IDV组进行了回顾性和多中心研究。 （CD4，病毒载量）。患者接受了2种NRTI，例如AZT + 3TC或D4T + 3TC联合EFV或IDV。主要的判断标准是治疗失败。我们评估了随访24个月后无法检测到病毒载量的患者百分比和3-4级不良反应的发生率。结果：两组患者的临床状态改善和机会性感染消退是相同的。 CD4的平均增益在EFV中优于177，而在IDV中则为+219（p = 0.004）。病毒载量无法检测的患者中，EFV为66％，IDV为59％（p = 0.04）。 EFV的不良反应发生率比IDV升高，分别为39％和23％（p = 0.002），但后来有所下降。结论：EFV的HAART在减少病毒载量和增加CD4计数方面至少与IDV一样有效，并且是一种出色的低成本一线治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号